Present and future treatment of pancreatic cancer

Semin Oncol. 2002 Jun;29(3 Suppl 9):23-31. doi: 10.1053/sonc.2002.34269.

Abstract

Gemcitabine has become a new standard for treatment of advanced pancreatic cancer. This development is based not only on drug efficacy but also on a favorable side-effect profile. Combinations of gemcitabine with antitumor drugs such as cisplatin, 5-fluorouracil, docetaxel, irinotecan, oxaliplatin, or capecitabine, and biological agents such as cetuximab or trastuzumab, have yielded promising results in phase II trials. However, none of these combinations has yet reached the level of an evidence-based standard treatment.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Deoxycytidine / administration & dosage*
  • Deoxycytidine / analogs & derivatives*
  • Docetaxel
  • Enzyme Inhibitors / therapeutic use
  • Fluorouracil / administration & dosage*
  • Gemcitabine
  • Humans
  • Paclitaxel / administration & dosage
  • Paclitaxel / analogs & derivatives*
  • Pancreatic Neoplasms / drug therapy*
  • Taxoids*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Paclitaxel
  • Fluorouracil
  • Gemcitabine